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to Republic Ministry of health of Serbia. In next regulatory step, after 
getting demand of Ministry of health of Serbia, ALIMS experts have 
to re-evaluate all registration documentation and their own decision 
in order to issue final decision.
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Introduction: BRINAVESS® /vernakalant/ is an antiarrhythmic med-
icine that acts preferentially in the atria to prolong atrial refractori-
ness and to rate dependently slow impulse. Anatomical Therapeutic 
Chemical Classification/ATC/ is: C01BG11.
Patients (or Materials) and Methods: According to Serbian Law 
on Medicinal Products and Medical Devices, regulatory procedural 
steps taken for getting Marketing Authorisation Approval in Serbia, 
started on 2011 year.
Results: After evaluation and reevaluation of submitted documenta-
tion/Module 1-5 Common Technical Document/, Advising Working 
Group for medicinal products of Medicines and Medical Devices 
Agency of Serbia suggested refusal application. On June 2012.year 
ALIMS issued the final decision/No. 515-01-0020-11-003/ about 
refusal registration. The reasons are related to divergence of facts 
cited in Summary Product Characteristics and pre-registration clini-
cal trials’ results devoted to efficacy, safety, statistical significance 
of total number of patients included in clinical phase of drug devel-
opment, as well as suspicion about the drug quality. Although the 
applicant declared that specified impurity limits in active substance 
are in accordance with preclinical toxicological testing, these results 
did not existed in Drug Master File, so the ALIMS assessor concluded 
that this applicant’s statement is not true.
Conclusion: Impossibility to submit requested additional revelant 
regulatory data caused applicant’s claim on March 2013.year for 
withdrawing registration of BRINAVESS® in Serbia.
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Introduction: Study of ethical aspects of relationships of pharma-
cists and patients during rendering of pharmaceutical services for 
the purpose of improving effectivness and safety of pharmacotherapy 
of patients.
Patients (or Materials) and Methods: A social poll using a method 
of selective anonymous survey of pharmacists and customers. The 
objects of research were the chemist’s shops of the city of Bishkek 
determined randomly. The analysis is based on the survey of 121 
pharmacists and 207 patients. The pharmacists were 45 (37.2%) 
specialists with university education and 76 (62.8%) with college 
education, the average age was 31.4 and the work of experience in 
pharmacy was 7.2 years. The patients were respondents older 18 
years old. The age distribution was 28.8% for 18–27; 34.6% for 
28–37; 9.7% for 38–47; 22.7% for 48 –57 and 4.2% for older 60. 
In terms of gender, the customers broke down into 133 (64.3%) 
female and 76 (35.7%) male. 45.3% of them had a university edu-
cation, 32.7% had a college education, and 21,9% were students. 
The received data were processed with the help of specialized SPSS 
statistical software package.
Results: According to the processed data most pharmacists (72,7%) 
know about the Code of Ethics for pharmacy practice and its con-
tents. All specialists (100%) admit that customers have the right to 
receive the information about the medicine they buy. As pharmacists 
note (64.5%), customers are most often interested in dosage and 
proper use of medicines. 63.6% of patients need professional assis-
tance when they choose a medicine. However, 27.1% of patients 
say pharmacists give consultations reluctantly. In the course of the 
research, customers of the chemist’s shops were suggested to evaluate 
some indices reflecting the degree of their satisfaction by pharmacists’ 
work (10-point scale). The average evaluation of the indices, such 
as appearance, consideration, tactfulness, patience and the ability 
to turn medical notions into plain language was 7.5. According to 
23.4% of pharmacists the most often reason of conflicts in chemist’s 
shops is patients’ dissatisfaction with a price of a medicine. This is 
confirmed by 67.7% patients thinking that most pharmacists are 
oriented for selling expensive and advertised medicines regardless 
of other affordable generics which do not concede in quality and 
effectiveness.
Conclusion: The research has revealed significant gaps in profes-
sional ethics of pharmacists. This allows us to make a conclusion that 
measures of interference in relationships of pharmacists and patients 
in the process of rendering pharmaceutical services need to be taken.
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Introduction: CXCL10 is a potent mast cell chemoattractant respon-
sible for the mast cell myositis characteristic of asthma. We have 
identified human airway smooth muscle (HASM) as a rich source 
of CXCL10 which is increased by TNF-alpha and IFN-gamma. We 
have previously shown that beta-agonists inhibit TNF-alpha induced 
CXCL10 release but the effect is lost when IFN-gamma is given 
concomitantly through poorly defined mechanisms. Here we defined 
the mechanism involved.
Patients (or Materials) and Methods: HASM cells taken from 3 nor-
mal donors were cultured using standard techniques. ELISA was 
used for quantitative measurement of CXCL10 release. Cyclic AMP 
assay was used to measure the cAMP level. Western Blot was used 
to indicate CREB phosphorylation.
Results: We found that salmeterol time dependently increased cAMP 
generation. TNF-alpha or IFN-gamma alone or in combination had 
similar effects on salmeterol time dependently induced cAMP genera-
tion suggesting that the inhibitory effect of IFN-gamma on beta-2 
agonist signaling was not at the level of cAMP generation but rather 
was likely to be an effect on downstream signaling pathways. Next 
we looked at the phosphorylation of CREB by Western blot and 
found that salmeterol and caused phosphorylation of CREB but this 
was differentially affected by the cytokines. Whereas TNF-alpha 
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alone was without effect but in combination with IFN-gamma mark-
edly impaired the ability of the long-acting beta-agonist to phospho-
rylate CREB. This suggests a novel mechanism whereby IFN-gamma 
interferes with beta-agonist signaling by impairing phosphorylation 
of CREB. This may be important in reducing the responses to beta-
agonists in refractory asthma.
Conclusion: IFN-gamma interferes with beta-2 agonist signaling 
by impairing phosphorylation of CREB. This may be important in 
reducing the responses to beta-agonists in refractory asthma.
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Introduction: Ulcerative colitis is an inflammatory chronic disease 
primarily affecting the colonic mucosa; the extent and severity of 
colon involvement are variable. The cause of UC remains unknown. 
However, some findings recently point to an overstimulation or inad-
equate regulation of the mucosal immune system as a major patho-
physiologic pathway. The role of angiotensin-converting enzyme 
blockers or angiotensin receptor blockers in the possible modulation 
of colon inflammation had not been verified. This prompted us to 
assess and compare the possible protective and therapeutic effects of 
captopril and valsartan on the extent and severity of ulcerative colitis 
induced by acetic acid in rats and to study the possible underlying 
mechanism of action of these drugs.
Patients (or Materials) and Methods: Seventy male Wistar albino 
rats were used. The animals were randomly divided into 7 groups 
each of 10 rats. Group 1: Normal control group, received Arabic 
gum PO 0.5 mlkg–1 (using gavage for all groups). Group 2: Acetic 
acid control group given 2 mL/rat 3% acetic acid rectally and Arabic 
gum PO for 2 weeks before induction of colitis. Group 3: Acetic acid 
control group 2 mL/rat 3% acetic acid rectally and Arabic gum PO 
for 2 weeks after induction of colitis. Group 4: Taken captopril HCl 
dissolved in Arabic gum at a dose of 30 mgkg-1 PO daily for 2 weeks 
before induction of ulcerative colitis. Group 5: Taken valsartan dis-
solved in Arabic gum at a dose of 30 mgkg-1 PO daily for 2 weeks 
before induction of ulcerative colitis. Group 6: Taken captopril HCl 
at a doses of 30 mgkg-1 PO once daily for 2 weeks after induction 
of UC. Group 7: Taken valsartan in a doses of 30 mgkg-1 PO once 
daily for 2 weeks after induction of ulcerative colitis.
Results: The results were assessed by histologic assessment of 
colonic tissues and measurement of malondialdehyde (MDA), tumor 
necrosis factor (TNF-α ), transforming growth factor (TGF-1b), 
angiotensin-converting enzyme (ACE), reduced glutathione (GSH), 
and platelet activating factor (PAF) levels in colonic tissues. Oral pre-
treatment with captopril or valsartan in a dose of 30 mgkg-1 body 
weight (prophylactic groups) and continuously for 2 weeks after 
induction (therapeutic groups) significantly reduce MDA, TNF-α , 
PAF, TGF-1b, and ACE levels in colonic tissues as compared with 
acetic acid control group. Also, a significant increase in GSH level 
was observed in colonic tissues. Captopril and valsartan attenu-
ated the macroscopic and microscopic colonic damage induced by 
acetic acid.
Conclusion: These results suggest that either captopril or valsar-
tan may be effective as prophylactic or treatment of UC through 
inhibition of ACE and scavenging effect on oxygen-derived free 
radicals.
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Introduction: Nonsteroidal anti-inflammatory drugs represent 1 of 
the most widely prescribed drugs used for treatment of pain and 
inflammation. The prescription of current existing anti-inflammatory 
drugs is hampered by their adverse effects over time. In the recent 
years, there is an upsurge in the areas related to newer developments 
in the prevention of disease especially the role of free radicals and 
antioxidants. Phenolic compounds are receiving increased attention 
as epidemiologic studies have highlighted the association between the 
consumption of polyphenolic–rich food and beverages and the pre-
vention of various human diseases. The present study investigated the 
analgesic and anti-inflammatory effects of chlorogenic acid (CGA), a 
polyphenolic compound present in many foods and beverages using 
carrageenan (Carr)-induced paw edema in rats and formalin – induce 
analgesia in mice.
Patients (or Materials) and Methods: Swiss mice (25–35 g) and 
Wistar rats (180–220 g), were used, chemicals and drugs (Formalin, 
Carrageenan, Indomethacin, CGA). Elisa Kits were used to study the 
effect of CGA on Carr-induced paw edema, 0.1 mL of 1% suspen-
sion of Carr in 0.9% Nacl solution was injected. The antinociceptive 
effects of CGA were tested by the formalin- induced hindpaw licking 
procedure in the day light. Elisa Kits were used to study the effects of 
CGA on some indices of oxidative stress. Reduced Glutathione and 
Malondialdehyde in paw tissues.
Results: Treatment of rats with CGA (50, 100, 150 mg/kg) signifi-
cantly reduced the rats paw edema induced by Carr and the formalin- 
induced pain in mice (P < 0.05) as compared with control groups. A 
significant reduction in rat paw volume in nitric oxide induced edema 
was observed (P < 0.05).CGA produced a significant reduction in 
malondialdehyde and significant increase in reduced glutathione in 
paw tissues (P < 0.05).
Conclusion: These results confirm that CGA has both analgesic and 
anti-inflammatory properties that may be related to the ability of 
this polyphenol to reduce the levels of superoxide and peroxynitrite 
anion radicals. CGA showed a promising potential drug of natural 
anti-inflammatory property to control oxidative stress.
Disclosure of Interest: None declared.
PP259—thE ABIlIty of ANtI-S100 ANtIBodIES 
to AmElIoRAtE thE SEVERIty of 
EXPERImENtAl AllERgIc ENcEPhAlomyElItIS 
IN wIStAR RAtS
J.L. Dugina1*; I.N. Abdurasulova2; I.A. Ertuzun1; and O.I. Epstein1
1Materia Medica Holding Company, Moscow; and 2Research 
Institute of Experimental Medicine RAMS, Saint-Petersburg, 
Russian Federation
Introduction: The pharmacologic profile of antibodies to S100 pro-
tein (anti-S100) in release-active form has been studied since 1998. 
Animal studies revealed that they possess anxiolytic-like, antidepres-
sant-like, and neuroprotective activity. GABA-ergic system as well as 
sigma1 receptor are involved in the realization of their effects. The 
aim of the present study is to assess the influence of anti-S100 treat-
ment on the course of experimental allergic encephalomyelitis (EAE).
Patients (or Materials) and Methods: EAE was induced female 
Wistar rats (200–220 g) by a single subcutaneous inoculation of a 
spinal cord homogenate emulsified in complete Freund’s adjuvant 
(100 mg of homogenate of homologous spinal cord, 0.2 mL CFA, 
